Changes in left ventricular volume, ejection fraction and NHYA functional class
| Azosemide | Furosemide | |||||
|---|---|---|---|---|---|---|
| In both groups | Baseline | 6 months | δ | Baseline | 6 months | δ |
| Echocardiography | ||||||
| LVEDV (mL) | 187±42 | 160±44* | −26±32 | 186±42 | 165±47† | −21±28 |
| LVESV (mL) | 126±38 | 99±40* | −27±28 | 128±45 | 106±48* | −22±27 |
| LVEF (%) | 33±8 | 38±10* | 6±9 | 31±9 | 36±11* | 5±10 |
| NYHA functional class | ||||||
| I/II/III/IV | 0/16/32/6 | 13/28/13/0* | 0/14/34/6 | 6/23/24/1*‡ | ||
Values are means±SD.
*p <0.001 vs Baseline, †p < 0.01 vs Baseline, ‡p < 0.01 vs Azosemide Group.
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVSDV, left ventricular end-systolic volume; NYHA, New York Heart Association.